user

Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM)

被引：0
|
作者：
Chen, CI
White, D
Kouroukis, CT
Stewart, AK
Howson-Jan, K
Larratt, L
Powers, J
Eisenhauer, E
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] QE II Hlth Sci Ctr, Halifax, NS, Canada
[3] Margaret & Charles Juravinski Canc Ctr, Hamilton, ON, Canada
[4] London Hlth Sci Ctr, London, ON, Canada
[5] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada
[6] Natl Canc Inst, Clin Trials Grp, Kingston, ON, Canada
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3288
引用
收藏
页码：896A / 896A
页数：1
相关论文
共 50 条
  • [21] Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome
    Holkova, Beata
    Shafer, Danielle
    Yazbeck, Victor
    Dave, Sandeep
    Bose, Prithviraj
    Tombes, Mary Beth
    Shrader, Ellen
    Wan, Wen
    Bandyopadhyay, Dipankar
    Weir, Caryn
    Collins, Elizabeth B.
    Garnett, Amanda
    Kmieciak, Maciej
    Roberts, John D.
    Garcia-Manero, Guillermo
    Grant, Steven
    LEUKEMIA & LYMPHOMA, 2021, 62 (05) : 1187 - 1194
  • [22] A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
    Manish A. Shah
    Derek G. Power
    Hedy L. Kindler
    Kyle D. Holen
    Margaret M. Kemeny
    David H. Ilson
    Laura Tang
    Marinela Capanu
    John J. Wright
    David P. Kelsen
    Investigational New Drugs, 2011, 29 : 1475 - 1481
  • [23] Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma.
    Popat, R
    Oakervee, HE
    Curry, N
    Foot, N
    Morris, C
    Drake, M
    Agrawal, S
    Smith, P
    Schenkein, D
    Esseltine, DL
    Cavenagh, JD
    BLOOD, 2005, 106 (11) : 717A - 718A
  • [24] The proteasome inhibitor PS-341 (Velcade®) in the treatment of pancreatic carcinoma.: Critical discussion of a phase II study
    Arit, Alexander
    Foelsch, Ulrich R.
    MEDIZINISCHE KLINIK, 2006, 101 (08) : 668 - 670
  • [25] Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenstrom Macroglobulinemia (WM)
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Laplant, Betsy
    Alegria, Victoria R.
    Elliott, Jamie B.
    Zimmerman, Ashley
    Heslop, Keisha
    Chapin, Dustin
    Sher, Taimur
    Roy, Vivek
    Rasheed, Ahsan
    Paulus, Aneel
    Chanan-Khan, Asher
    BLOOD, 2022, 140 : 9331 - 9332
  • [26] Predictive factors for response and progression after treatment with rituximab in previously untreated patients with Waldenstrom's macroglobulinemia (WM).
    Anagnostopoulos, A
    Treon, SP
    Zervas, K
    Branagan, A
    Gika, D
    Zomas, A
    Kyrtsonis, MC
    Vassou, A
    Anagnostopoulos, N
    Pangalis, G
    Dimopoulos, MA
    BLOOD, 2005, 106 (11) : 973A - 973A
  • [27] Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade™) in combination with pegylated liposomal doxorubicin (Doxil®) in patients with refractory hematologic malignancies.
    Orlowski, RZ
    Hall, M
    Voorhees, P
    Hogan, C
    Humes, E
    Johri, A
    Bell, H
    Garcia, R
    Adams, J
    Esseltine, D
    Gabriel, D
    Shea, T
    Van Deventer, H
    Mitchell, B
    Dees, EC
    BLOOD, 2002, 100 (11) : 105A - 105A
  • [28] Phase II trial of single agent bortezomib (VELCADE®) in patients with previously untreated multiple myeloma (MM)
    Richardson, PG
    Chanan-Khan, A
    Schlossman, RL
    Munshi, NC
    Wen, P
    Briemberg, H
    Kuter, D
    Oaklander, AL
    Lonial, S
    Hassoun, H
    Doss, D
    Colson, K
    McKenney, M
    Hande, K
    Koryzna, A
    Stoklas, B
    Lunde, L
    Gorelik, S
    McAlister, C
    Freeman, A
    Warren, D
    Collins, D
    Esseltine, D
    Amato, A
    Anderson, KC
    BLOOD, 2004, 104 (11) : 100A - 100A
  • [29] Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC)
    Li, Tianhong
    Ho, Liawaty
    Piperdi, Bilal
    Elrafei, Tarek
    Camacho, Fernando J.
    Rigas, James R.
    Perez-Soler, Roman
    Gucalp, Rasim
    LUNG CANCER, 2010, 68 (01) : 89 - 93
  • [30] Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study
    Ghobrial, Irene M.
    Harousseau, Jean-Luc
    Treon, Steven P.
    Harris, Brianna
    Lin, Courtney E.
    Yuan, Zheng
    Benhadji, Karim
    Wooldridge, James E.
    Leblond, Veronique
    BLOOD, 2009, 114 (22) : 1488 - 1488
12345